Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00025038
First received: October 11, 2001
Last updated: April 10, 2013
Last verified: January 2013
  Purpose

Giving chemotherapy drugs, such as R115777, isotretinoin, cytarabine, and fludarabine, before a donor bone marrow transplant or an umbilical cord transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. This phase II trial is studying how well giving combination chemotherapy together with donor bone marrow or umbilical cord blood transplant works in treating children with newly diagnosed juvenile myelomonocytic leukemia


Condition Intervention Phase
Juvenile Myelomonocytic Leukemia
Drug: tipifarnib
Drug: isotretinoin
Drug: fludarabine phosphate
Drug: cytarabine
Radiation: radiation therapy
Drug: cyclophosphamide
Biological: anti-thymocyte globulin
Procedure: allogeneic bone marrow transplantation
Procedure: double-unit umbilical cord blood transplantation
Procedure: umbilical cord blood transplantation
Other: laboratory biomarker analysis
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response rate (CR or PR) [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]
    The response rates in the up-front window with respect to whether or not patients had vas activating mutations will also be estimated by proportions.

  • Duration of response [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]
    Will be estimated by Kaplan-Meier method.

  • Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Will be estimated by Kaplan-Meier method.

  • Evaluation of prognostic importance of genetic marker [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]
    Logrank test and Cox proportional hazards model will be applied.

  • Grade 3 or greater toxicities assessed using CTC version 2.0 [ Time Frame: Up to 6 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Survival of patients receiving the window vs. not [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]
  • Response status on end of course reports (pre vs.post) [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]
    Signed-rank comparison of components of therapy will be done.


Enrollment: 100
Study Start Date: June 2001
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (tipifarnib, bone marrow/umbilical cord transplant)
See detailed description.
Drug: tipifarnib
Given orally
Other Names:
  • R115777
  • Zarnestra
Drug: isotretinoin
Given orally
Other Names:
  • 13-CRA
  • Amnesteem
  • Cistane
  • Claravis
  • Sotret
Drug: fludarabine phosphate
Given IV
Other Names:
  • 2-F-ara-AMP
  • Beneflur
  • Fludara
Drug: cytarabine
Given IV
Other Names:
  • ARA-C
  • arabinofuranosylcytosine
  • arabinosylcytosine
  • Cytosar-U
  • cytosine arabinoside
Radiation: radiation therapy
Undergo total body irradiation
Other Names:
  • irradiation
  • radiotherapy
  • therapy, radiation
Drug: cyclophosphamide
Given IV
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana
Biological: anti-thymocyte globulin
Given IV
Other Names:
  • ATG
  • ATGAM
  • lymphocyte immune globulin
  • Thymoglobulin
Procedure: allogeneic bone marrow transplantation
Undergo allogeneic bone marrow transplant
Other Names:
  • bone marrow therapy, allogeneic
  • bone marrow therapy, allogenic
  • transplantation, allogeneic bone marrow
  • transplantation, allogenic bone marrow
Procedure: double-unit umbilical cord blood transplantation Procedure: umbilical cord blood transplantation
Undergo allogeneic cord blood transplant
Other Names:
  • cord blood transplantation
  • transplantation, umbilical cord blood
  • UCB transplantation
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the response rate of children with newly diagnosed juvenile myelomonocytic leukemia treated with R115777, isotretinoin, cytarabine, and fludarabine followed by allogeneic bone marrow or umbilical cord blood transplantation.

II. Determine the safety and toxicity of this regimen in these patients. III. Determine the tolerability of this regimen in these patients. IV. Determine the rate of 2-year event-free survival of patients treated with this regimen.

V. Determine whether prognostic subsets of these patients can be identified based on expression of clinical, genetic (NFI, monosomy 7, RAS gene), or hematopoietic characteristics.

OUTLINE: This is a multicenter study.

Patients may choose to receive upfront window induction therapy with oral R115777 twice daily on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.

Patients with progressive disease or stable disease with unacceptable hematopoietic recovery after 1 course proceed to induction chemotherapy. (R11577 portion of the study closed to accrual as of 08/2005)

All patients receive induction chemotherapy comprising oral isotretinoin once daily beginning on day 1 and fludarabine IV over 30 minutes and cytarabine IV over 4 hours on days 1-5. Treatment with fludarabine and cytarabine repeats every 28 days for 2 courses. Treatment with isotretinoin continues until allogeneic bone marrow or umbilical cord blood transplantation. Patients with progressive disease after 1 course proceed to transplantation.

After completion of isotretinoin, patients receive a preparative regimen comprising total body irradiation twice daily on days -7 to -4, cyclophosphamide IV over 2 hours on days -3 and -2, and anti-thymocyte globulin IV over 4-6 hours every 12 hours on days -3 to -1. Patients undergo allogeneic bone marrow or umbilical cord blood transplantation on day 0. Patients receive oral isotretinoin daily beginning on approximately day 60 and continuing for 1 year.

Patients are followed every 6 months for 5 years and then annually thereafter.

PROJECTED ACCRUAL: A maximum of 100 patients (18-46 receiving R115777 with induction chemotherapy [R11577 portion of the study closed to accrual as of 08/2005] and 27-54 receiving induction chemotherapy only) will be accrued for this study within 3.2 years.

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed, previously untreated juvenile myelomonocytic leukemia
  • Presenting with all of the following:

    • Absence of t(9;22) or bcr/abl by PCR
    • Absolute monocyte count greater than 1,000/mm^3
    • Less than 20% bone marrow blasts
  • Presenting with at least 2 of the following:

    • Elevated F hemoglobin
    • Myeloid precursors in peripheral blood
    • WBC greater than 10,000/mm^3
    • Sargramostim (GM-CSF) hypersensitivity
  • See Disease Characteristics
  • Bilirubin no greater than 2.0 mg/dL
  • ALT no greater than 3 times normal
  • Creatinine no greater than 2 times normal
  • No concurrent sargramostim (GM-CSF)
  • No concurrent proton pump inhibitors
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00025038

Locations
United States, California
Children's Oncology Group
Arcadia, California, United States, 91006-3776
Sponsors and Collaborators
Investigators
Principal Investigator: Robert Castleberry Children's Oncology Group
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00025038     History of Changes
Other Study ID Numbers: NCI-2012-01861, AAML0122, U10CA098543, CDR0000068788
Study First Received: October 11, 2001
Last Updated: April 10, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukemia
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Bone Marrow Diseases
Hematologic Diseases
Antilymphocyte Serum
Cyclophosphamide
Cytarabine
Fludarabine monophosphate
Immunoglobulins
Fludarabine
Tipifarnib
Vidarabine
Isotretinoin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists

ClinicalTrials.gov processed this record on April 17, 2014